NTHI NeOnc Technologies Holdings, Inc.
Company Analysis
Latest News
NeOnc Technologies Holdings, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 17, 2026
NeOnc Technologies is expected to report a Q2 2026 consensus loss of $0.16 per share on zero revenue, with the stock currently trading at $4.22 against an...
🟢 NeOnc Technologies Holdings is trading 20% up today after positive Phase 2a NEO100 results
NeOnc Technologies Holdings is trading sharply higher on August 14, 2026, after positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant...
NeOnc Technologies Reports Positive Phase 2a Trial Results for Brain Cancer Drug NEO100
NeOnc Technologies Holdings announced positive top-line results from the Phase 2a portion of its NEO100-01 clinical trial for patients with recurrent IDH1...
🔴 NeOnc Technologies Holdings is trading 6.36% down today amid volatile post-catalyst trading
NeOnc Technologies Holdings is trading 6.36% down at $3.24, despite positive Phase 2a NEO100 results released August 12, 2026. - The study met its primary...
🔴 NeOnc Technologies Holdings is trading 11.95% down today; reason for decline remains unclear
NeOnc Technologies Holdings is trading 11.95% down at $3.83, with available coverage not identifying a clear reason for the decline. - August 12, 2026, Phase...
🔴 NeOnc Technologies Holdings is trading 5.29% down today
NeOnc Technologies Holdings is trading 5.29% down now at $4.12 after opening-day weakness on August 12, 2026; the immediate cause remains unclear. - The...
NTHI Reports Positive Phase 2a Results for NEO100 in Recurrent High-Grade Glioma
NeOnc Technologies announced positive topline results from the Phase 2a study of its lead candidate, NEO100, for patients with recurrent high-grade IDH1-mutant...
🟢 NeOnc Technologies Holdings is trading 14.58% up in pre-market ahead of August 12 NEO100 readout
NeOnc Technologies Holdings is trading 14.58% up at $4.98 now as investors position ahead of the August 12, 2026 topline Phase 2a readout for intranasal NEO100...
🟢 NeOnc Technologies Holdings is trading 24.52% up today ahead of August 12 Phase 2a NEO100 results
NeOnc Technologies Holdings is trading 24.52% up now at $4.36 as investors position ahead of the August 12, 2026, presentation of topline Phase 2a NEO100...
🟢 NeOnc Technologies Holdings is trading 6.28% up today ahead of August 12 NEO100 Phase 2a results
NeOnc Technologies Holdings is trading 6.28% up at $3.72 as investors focus on August 12 topline Phase 2a results for intranasal NEO100 in recurrent...
🟢 NeOnc Technologies Holdings is trading 13.31% up in pre-market ahead of August 12 NEO100 Phase 2a data
NeOnc Technologies Holdings is trading 13.31% up at $3.97 after confirming an August 12 presentation of topline Phase 2a NEO100 results in recurrent high-grade...
🟢 NeOnc Technologies Holdings is trading 5.71% up in pre-market ahead of August 12 NEO100 results
NeOnc Technologies Holdings is trading 5.71% up in pre-market at $3.70 after the company confirmed an August 12 presentation of topline Phase 2a NEO100 results...
NeOnc Technologies second quarter 2026 loss of $14.2M reflects ramped R&D ahead of clinical results
NeOnc Technologies reported a widened net loss for the second quarter 2026 as it increased investments in its clinical pipeline. The company is currently...
🟢 NeOnc Technologies Holdings is trading 12.29% up in after-hours trading before Phase 2a results
NeOnc Technologies Holdings is trading 12.29% up at $3.93 after announcing August 10, 2026, that it will report topline Phase 2a NEO100 results on August 12,...
NeOnc's Make-or-Break Cancer Drug Data Lands Tomorrow — Can a $3.75 Stock Survive the Verdict?
Shares of NeOnc Technologies Holdings jumped 7.1% to $3.75 on August 11, breaking out of a week-long flat line near $3.50, after the company confirmed it will...
🟢 NeOnc Technologies Holdings is trading 7.14% up in after-hours trading after confirming August 12 NEO100 data
NeOnc Technologies Holdings is trading 7.14% up now at $3.75 in after-hours trading after confirming topline Phase 2a NEO100 data for August 12. - The company...
🟢 NeOnc Technologies Holdings is trading 7.14% up in pre-market without a confirmed catalyst
NeOnc Technologies Holdings is trading at $3.75, up +7.14% in pre-market, with no confirmed company-specific catalyst identified. - No company-specific...
🟢 NeOnc Technologies Holdings is trading 5.7% up in after-hours trading — possibly on NEO100-01 data
NeOnc Technologies Holdings is trading at $3.70 (+5.71%) in after-hours trading, with investor attention possibly reflecting upcoming NEO100-01 Phase 2a data...
🟢 NeOnc Technologies Holdings is trading 5% up today amid a sector-wide biotech rally and risk-on sentiment
NeOnc Technologies Holdings is trading at $3.67 (5% up) in pre-market, extending gains from the previous week. • The upward move follows a July 31, 2026,...
🟢 NeOnc Technologies Holdings is trading 6.1% up today amid risk-on sentiment and sector-wide biotech rally
NeOnc Technologies Holdings is trading 6.1% higher at $3.70 as broader market optimism and strong large-cap tech earnings fuel a risk-on rally across the...